Paula Park, PhRMA urges more disclosure, The Scientist, July 9, 2004. Excerpt: "A new set of guidelines issued by the Pharmaceutical Research and Manufacturers of America (PhRMA) calling for the release of more data from clinical trials is being met with guarded skepticism by advocates who have been clamoring for increased transparency....An American Medical Association (AMA) trustee welcomed the PhRMA guidelines, but questioned their potential effectiveness and said they do not go far enough. All clinical trials—not just those for marketed drugs—should be added to a public registry, said trustee Joseph Heyman, and institutional review boards should require registration as a condition of allowing the study to continue. Even trials on therapies that are later discarded provide significant information to scientists, Heyman added. For marketed drugs, it's important to release information on all studies, even the most exploratory ones."
Posted by
Peter Suber at 7/09/2004 03:58:00 PM.
The open access movement:
Putting peer-reviewed scientific and scholarly literature
on the internet. Making it available free of charge and
free of most copyright and licensing restrictions.
Removing the barriers to serious research.
